Real-world trials highlighting the predictive value of IsoPSA

Panelists discuss how real-world trial data provides important validation for IsoPSA’s predictive value. They reference a large retrospective study that followed over 1,500 men, demonstrating a strong correlation between high IsoPSA indices and future risk of clinically significant prostate cancer. Patients with low IsoPSA indices showed a very low likelihood of progression, supporting its role as a long-term risk stratification tool.

Panelists discuss how these findings suggest IsoPSA can reduce overtreatment by safely identifying men who may defer biopsy. The ability to predict 30-month risk trajectories provides clinicians with a valuable reference point for follow-up planning. Incorporating IsoPSA into initial evaluation could therefore minimize unnecessary procedures and help prioritize high-risk patients for timely interventions.

Panelists discuss how trial results also show a clear association between IsoPSA scores and MRI findings, reinforcing its complementary role alongside imaging. This evidence strengthens confidence in IsoPSA as a reliable tool across different practice settings, paving the way for guideline incorporation. The panel agrees that real-world validation is critical to expanding clinical adoption.